Cipla Limited (NSE:CIPLA)
| Market Cap | 1.23T |
| Revenue (ttm) | 279.66B |
| Net Income (ttm) | 54.41B |
| Shares Out | 807.77M |
| EPS (ttm) | 67.32 |
| PE Ratio | 22.68 |
| Forward PE | 26.61 |
| Dividend | 13.00 (0.85%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 896,725 |
| Average Volume | 1,538,709 |
| Open | 1,526.90 |
| Previous Close | 1,526.80 |
| Day's Range | 1,519.40 - 1,534.80 |
| 52-Week Range | 1,335.00 - 1,673.00 |
| Beta | 0.10 |
| RSI | 48.01 |
| Earnings Date | Oct 30, 2025 |
About Cipla
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obe... [Read more]
Financial Performance
In 2024, Cipla's revenue was 272.67 billion, an increase of 6.78% compared to the previous year's 255.37 billion. Earnings were 52.73 billion, an increase of 27.93%.
Financial StatementsNews
Top stocks to watch today, November 4, 2025: Bharti Airtel, Titan, Cipla, IEX, Indus Towers, Hero Moto, Power Grid, and more
Indian stock markets are set for an action-packed session on Tuesday, November 4, 2025, with several heavyweight companies releasing quarterly...
Cipla to acquire 100% stake in Inzpera Healthsciences for Rs 110.65 crore
Cipla Limited has announced that it has entered into definitive agreements to acquire 100 percent stake in Inzpera Healthsciences Limited,...
Nifty 50 top losers today, October 31: Eternal, NTPC, Cipla, Max Healthcare, HDFC Life, HDFC Life and more
Indian benchmark indices ended lower on October 31, with both Sensex and Nifty closing in the red amid broad-based weakness...
Cipla Ltd (BOM:500087) Half Year 2026 Earnings Call Highlights: Record Revenue and Strategic US ...
Cipla Ltd (BOM:500087) Half Year 2026 Earnings Call Highlights: Record Revenue and Strategic US Market Moves
Cipla's leadership change: Achin Gupta to succeed Umang Vohra
India Business News: Cipla, India’s third largest drugmaker by sales, will see a change of guard from April 1, 2026 with its MD and global CEO Umang Vohra stepping down. T.
Half Year 2026 Cipla Ltd Earnings Call Transcript
Half Year 2026 Cipla Ltd Earnings Call Transcript
Cipla names Achin Gupta as next MD & Global CEO; Umang Vohra to step down in 2026
Cipla Limited has announced a major leadership transition, setting the stage for a new era at the Mumbai-headquartered pharmaceutical company....
Cipla CEO Umang Vohra says Q2 marks ‘highest-ever quarterly revenue’; highlights obesity launch, US traction and emerging markets push
Cipla’s Managing Director and Global CEO Umang Vohra said the company delivered its highest-ever quarterly revenue in Q2 FY26, supported...
Cipla to launch 7 new products by 2026, sharpens focus on respiratory and peptide therapies
Cipla is gearing up for a major expansion in its product pipeline, outlining plans to launch seven new products by...
Cipla Q2 FY26 Results: Revenue rises 8% to Rs 7,589 crore, Net Profit up 3.7% YoY
Cipla reported its financial results for the second quarter ended September 30, 2025, posting a modest performance marked by steady...
Top Q2 results today, October 30: Adani Power, NTPC, ITC, Cipla, Swiggy, Hyundai Motor India, Dabur India and more to announce earnings
More than 85 Indian companies are set to announce their Q2 FY25 earnings results today, October 30, making it one...
Nifty 50 top losers today, October 24: Cipla, Hindustan Unilever, Max Healthcare, UltraTech, Kotak Mahindra Bank, UltraTech Cement and more
Indian equity markets ended in the red on October 24, with both benchmark indices slipping into negative territory. The Sensex...
Lilly and Cipla tie up to broaden access of weight-loss therapy
India News: Eli Lilly and Cipla announced an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak. This strategic agreement.
Eli Lilly (LLY) Partners with Cipla to Market Tirzepatide in India
Eli Lilly (LLY) Partners with Cipla to Market Tirzepatide in India
Nifty top gainers today, October 10: Cipla, SBI, Maruti Suzuki India, Bajaj Auto, Dr. Reddy’s Laboratories and more
Indian equity markets ended higher on October 10, with the Nifty hovering around 25,300. The Sensex closed at 82,500.82, up...
Nifty top gainers today, September 30: JSW Steel, UltraTech, Adani Ports, Tata Motors, Cipla and more
The benchmark indices ended lower in today’s session. The Sensex closed at 80,267.62, down 97.32 points or 0.12%, while the Nifty settled at 24,611.10, lower by 23.80 points or 0.10%. Despite the broa...
Trump’s 100% tariffs on branded drugs: Which Indian pharma stocks are most vulnerable? Experts weigh in
Donald Trump's tariff move impacts Indian pharma stocks. Companies like Sun Pharma, Cipla, and Dr. Reddy's face potential declines. US represents a major market for Indian exports.
Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on D-Street
Pharmaceutical stocks, particularly Indian firms, plummeted following President Trump's announcement of 100% tariffs on imported branded medicines to the US. Companies like Sun Pharma, Biocon, and Zyd...
Indian pharma stocks in focus as Trump announces 100% tariff on branded drugs
Indian pharma shares such as Sun Pharma, Lupin, Dr. Reddy’s, Cipla, and Aurobindo Pharma are in focus after Donald Trump announced a 100% tariff on imported branded drugs, effective October 1, unless ...
Stock market live updates today: Indian share market updates, Sensex & Nifty on 25 Sept 2025
Welcome to Business Upturn’s live coverage of the Indian stock market on Thursday, 25 September 2025. The trading session is expected to remain stock-specific as several companies announced key develo...
Nifty 50 top losers today, September 22: Tech Mahindra, TCS, Infosys, Cipla, Wipro, HCL Technologies and more
Indian benchmark indices ended the session on a cautious note on September 22. The Sensex fell 466.26 points to 82,159.97, while the Nifty slipped 124.70 points to 25,202.35. Here’s a look at Nifty to...
Nifty top gainers today, September 18: Eternal, HDFC Life, Sun Pharma, Cipla, Infosys and more
Indian equity benchmarks closed higher on September 18. The BSE Sensex rose 320.25 points, or 0.39%, to end at 83,013.96, while the NSE Nifty 50 gained 93.35 points, or 0.37%, to finish at 25,423.60. ...
Nifty 50 top losers today, September 15: Cipla, Asian Paints, Mahindra & Mahindra, Shriram Finance, Dr. Reddy’s and more
Indian equity markets ended on a subdued note on September 15, with benchmark indices slipping in a rangebound session. The Sensex fell 118.96 points, or 0.15 percent, to 81,785.74, while the Nifty cl...
Nifty top losers this week (ending September 5): HCL Technologies, Wipro, Cipla, Infosys, HDFC Life and more
Indian equity benchmarks ended the week higher, with the Sensex up 1.3% and the Nifty 50 rising 1.1% after the GST Council’s decision to reduce levies on essential goods. Despite the weekly gains, mar...
Nifty 50 top losers today, September 5: ITC, Cipla, HCL Technologies, TCS, Tech Mahindra and more
Indian benchmark indices ended largely flat in a choppy trading session on September 5. While the Sensex slipped marginally by 7.25 points to close at 80,710.76, the Nifty managed a slight gain of 6.7...